研報掘金丨民生證券:丸美生物打造第二成長曲線,維持“推薦”評級
民生證券研報指出,丸美生物(603983.SH)投資標的摩漾生物CAHA面部填充劑獲批,公司“雙美”戰略佈局更進一步。摩漾生物Aphranel為目前國內唯一一款合規的CaHA 面部填充劑產品,丸美生物前瞻性進行投資彰顯公司在醫美領域的戰略眼光。彰顯公司在醫美領域的戰略眼光,同時也有助於提升公司在再生醫學領域的地位和影響力。公司持續深化“雙美”戰略,打開公司成長空間。公司是國內眼部護理及抗衰領域龍頭企業,主品牌丸美積極調整渠道與產品結構恢復穩健增長,新鋭彩粧品牌戀火差異化深耕底粧賽道打造第二成長曲線,看好公司未來品牌力、產品力提升驅動收入增長,維持“推薦”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.